Key facts
- QbDVision’s last known valuation is $53.0M (Apr 2025).
- It has raised $32.6M across 1 recorded rounds; the latest was Early Stage VC ($13.0M) in Apr 2025.
- Notable investors include S3 Ventures, ATX Venture Partners, Hudson Park Advisors, Buena Vista Angels, Cartmell — 8 tracked in total.
- QbDVision has filed 1 Form D with the SEC, most recently Apr 2025 ($13.0M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for QbDVision
Funding rounds
1 roundsAbout QbDVision
Developer of a product life cycle management platform designed to provide a digital way to manage development processes. The company's platform collects all the teams' data and knowledge in one searchable and cloud-based hub and integrates the product, process, and quality workflows, enabling biopharma organizations to increase the probability of technical success and help get therapeutic breakthroughs to patients quickly.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2017
- Employees
- 45
- Website
- qbdvision.com/
- Ownership
- Privately Held (backing)
QbDVision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QbDVision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QbDVision in its N-PORT filings yet. We sweep new filings monthly.